Each acquisition platform opens to new investors on its own timeline — tied to active deal flow and integration capacity. All securities are offered directly by Cebron Financial Group, Inc.
Alongside direct equity participation in individual platforms, Cebron Financial Group, Inc. offers accredited investors a fixed income instrument that provides current quarterly income from day one, a contractual maturity at 36 months, and a Profit Participation Right tied to platform EBITDA performance — combining the income reliability of private credit with the upside mechanics of acquisition compounding.
The CFG Senior Secured Note pays 10% per annum in quarterly cash distributions for a fixed 36-month term. Notes are issued directly by Cebron Financial Group, Inc. — the Delaware parent holding company — and are supported by the operating performance and fee income of CFG’s portfolio of acquisition platforms and M&A advisory activities.
An Early Call Option is available beginning at month 18: CFG may redeem all outstanding Notes at par plus accrued interest if defined platform performance thresholds are met, providing investors with an accelerated return of principal pathway.
10% annual interest paid quarterly in cash — plus a one-time Profit Participation bonus of up to 20% of principal if CFG’s platforms achieve defined EBITDA milestones within 30 months of issuance.
Profit Participation Right (PPR) — a contractual bonus of 5–20% of principal paid as a one-time distribution if CFG’s platforms achieve defined EBITDA milestones within 30 months of the Note’s issuance date.
Complete offering documents, subscription agreement, and PPR milestone definitions are available to verified investors through the Cebron Capital investor portal.
Offered by Cebron Financial Group, Inc. · U.S. Reg D 506(c) · International Reg S
Not an offer to sell. Offers made only via official offering memorandum.
The PPR pays a one-time bonus at the close of the 30-month measurement window based on aggregate EBITDA achieved across CFG’s acquisition platforms. Specific thresholds for each tier are defined in the offering documents available to verified investors.
Threshold milestone — base platform EBITDA target achieved within 30 months
Accelerated milestone — mid-tier EBITDA reflecting compounding across multiple acquisitions
Maximum milestone — full EBITDA target reflecting successful multi-platform execution at scale
SensQor is CFG’s environmental and geotechnical engineering platform — acquiring founder-owned firms serving infrastructure owners, energy companies, and industrial clients across the United States. The environmental engineering sector is one of the most fragmented professional services markets in the country: thousands of independent firms, each below institutional acquisition radar, each generating defensible recurring revenue from compliance-driven and project-based work.
SensQor acquires at disciplined lower-middle-market multiples in a sector where consolidation is structurally early — the largest players control a small fraction of total market revenue, and the average acquisition target has no defined succession plan and no path to growth capital beyond its founding geography.
“Compliance-driven demand, geographic fragmentation, and founder succession dynamics create an extended acquisition runway at multiples that institutional capital cannot access at scale.”
COS margin expansion: Founder-operator firms carry meaningful margin improvement opportunity through overhead rationalization, pricing discipline, and cross-platform procurement
Direct equity participation in the SensQor acquisition platform
SensQor equity investors hold a direct economic interest in the platform’s acquisition compounding model — participating in value creation as the platform acquires businesses, expands margins through the Cebron Operating System, and builds toward an institutional exit at a higher valuation multiple.
Full equity structure, deal terms, platform details, and subscription documents are available after free accredited investor verification.
Offered by Cebron Financial Group, Inc. · U.S. Reg D 506(c) · International Reg S
EntelMed is CFG’s medical and healthcare technology platform — acquiring manufacturers, distributors, and specialized service providers in the orthopedic device and surgical instrument market. This sector operates with structural characteristics that make it one of the most durable compounding environments in the U.S. lower-middle market: deep surgeon relationships built over years, high switching costs, long product approval cycles that protect incumbents, and a fragmentation profile barely touched by institutional consolidators.
EntelMed focuses below the threshold where large-cap medical device companies compete — specialized, founder-run businesses serving specific surgical specialties whose products and services command premium margins precisely because they are not commodities.
“Long surgeon relationships, regulatory barriers to substitution, and the absence of institutional consolidators below $50M revenue create sustainable acquisition multiples and significant post-acquisition margin opportunity.”
Surgeon relationship moats: Clinical relationships between device reps and surgeons are among the most durable competitive advantages in any industry — they do not reprice when a competitor lowers their price
Direct equity participation in the EntelMed acquisition platform
EntelMed equity investors hold a direct economic interest in the platform’s acquisition program — participating in the compounding mechanics of acquiring orthopedic device and medical technology businesses, integrating them through the COS, and scaling toward institutional revaluation.
Full equity structure, deal terms, platform details, and subscription documents are available after free accredited investor verification.
Offered by Cebron Financial Group, Inc. · U.S. Reg D 506(c) · International Reg S
Direct equity participation in the SensQor acquisition platform
Cenovix is CFG’s biotechnology and laboratory services platform — consolidating specialized laboratory and biotech services businesses serving pharmaceutical companies, research institutions, and clinical trial operators. Cenovix is currently focused on integrating its most recent acquisitions through the Cebron Operating System and building the management infrastructure required to support the next acquisition phase.
The platform is expected to open to new investors in Q3 2026 when current integration milestones are achieved. Investors on the waitlist will receive advance notice before any new round is announced publicly. Waitlist registration carries no investment obligation.
“Accreditation requirements, embedded client workflows, and the high cost of switching providers create client retention that protects post-acquisition cash flows better than most sectors.”
Regulatory moats: CAP accreditation, CLIA certification, and GLP compliance protect incumbent laboratories from new entrants at nearly every market segment
Embedded workflows: Pharmaceutical and clinical trial clients integrate laboratory partners deeply — switching costs are measured in months of transition time, not price differentials
Long-duration relationships: Multi-year pharma development programs create revenue visibility well above the norms for lower-middle-market services businesses
Currently in integration phase: Cenovix is applying the COS across recent acquisitions — margin expansion before new deal activity is the pattern that precedes institutional revaluation
Currently in integration phase. Join the waitlist for priority access when Cenovix opens.
Cenovix is targeting a Q3 2026 investor opening, subject to the completion of current integration milestones and platform readiness review. Waitlist members receive advance notice before any public announcement.
The platform is focused on integrating recent acquisitions and building the infrastructure for its next acquisition phase. Allocation will open when integration milestones are achieved and the platform is positioned for its next growth round.
No commitment. No spam. A single notification when Cenovix opens to investors. Verification will be required to invest.
Seqara is CFG’s digital security and cybersecurity platform — designed to consolidate cybersecurity services, managed security operations, and digital risk management firms serving enterprise, government, and critical infrastructure clients. Seqara is currently in the platform build phase: the acquisition thesis is defined, the management team is being assembled, and the initial deal pipeline is in development.
The cybersecurity services market is one of the most structurally compelling consolidation targets in the lower-middle market: non-discretionary demand driven by regulation and risk, a fragmented provider base of regional specialists, and an accelerating threat environment that structurally advantages providers with broader capabilities and scale.
“Regulatory mandates, accelerating threat complexity, and enterprise demand for integrated security coverage reward the platform consolidator that can deliver breadth and depth that regional specialists cannot.”
Non-discretionary demand: Cybersecurity spend is driven by compliance requirements (CMMC, NIST, SOC 2, FedRAMP) and board-level risk mandates — not discretionary IT budgets
Certification and clearance barriers: CMMC compliance, federal clearance requirements, and SOC certifications protect experienced providers from fast-follower competition
Recurring revenue profile: Managed security services and retainer-based monitoring create predictable, multi-year revenue streams with high switching costs
Early-stage access: Waitlist investors have priority access to Seqara’s first investment round at platform entry terms not available to later-stage participants
Early platform build phase. Join the waitlist for first-round access when Seqara opens.
Seqara is targeting a Q3 2026 opening to investors, timed to the identification of its first acquisition target and finalization of the capital structure for that transaction. Waitlist members receive advance notice before any public announcement.
Seqara is in the early platform build phase — executive team assembly, thesis refinement, and initial deal pipeline development are underway. Waitlist members receive advance notice before any public announcement.
No commitment. No spam. A single notification when Cenovix opens to investors. Verification will be required to invest.
UIM Labs is CFG’s AI, autonomy, and advanced technology platform — consolidating companies operating at the intersection of artificial intelligence, autonomous systems, and defense-adjacent technology. Headquartered in Irvine, California, UIM Labs brings together government and industry through strategic alliances focused on cyberspace operations, multi-domain AI deployment, and high-performance computing applications.
UIM Labs products span vehicle-to-vehicle communication (V2V Communicator), industrial digitalization (SmartStream Connect), AIOps, DevOps, AI/ML, and autonomy solutions. The platform is in the early build phase and is expected to open to new investors in Q3 2026.
“Government-aligned AI and autonomy companies operating in multi-domain environments represent one of the most defensible positions in the technology sector — combining mission-critical demand with barriers to substitution that commercial AI companies cannot replicate.”
Government and defense alignment: Seqara’s Cyberspace Initiative creates strategic alliances between government and industry for cyberspace operations and defense technology — establishing durable institutional relationships
Multi-domain AI platform: AIOps, DevOps, AI/ML, and autonomous systems capabilities position UIM Labs across the full technology stack required for enterprise and defense clients
Industrial digitalization tailwind: SmartStream Connect targets the physical-to-software-defined industrial transformation — a multi-decade demand cycle across manufacturing, logistics, and infrastructure
Early-stage access: Waitlist investors have priority access to UIM Labs’ first investment round at platform entry terms that reflect the platform’s current stage — before institutional capital enters
Early platform build phase. Join the waitlist for first-round access when UIM Labs opens.
UIM Labs is targeting a Q3 2026 opening to investors, subject to first acquisition identification and capital structure finalization. Waitlist members receive advance notice before any public announcement.
UIM Labs is in the early platform build phase — strategic thesis refinement, management team assembly, and initial acquisition pipeline development are underway. Platform will open to investors when the first acquisition target is identified and the capital structure for that transaction is finalized.
No commitment. No spam. A single notification when Cenovix opens to investors. Verification will be required to invest.
Register once to receive advance notice when any CFG platform opens to investors — including Cenovix, Seqara, and UIM Labs targeting Q3 2026, the CFG Notes reaching a new tranche, or a future platform entirely. Priority notification before any public announcement.
No commitment. No spam. Verification required to invest.
SensQor equity, EntelMed equity, and CFG Senior Secured Notes are all currently open to verified investors. Create your account, complete free verification, and access full offering documents for each open opportunity.